Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 32

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 32
---

actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information,
future events or otherwise.

In addition, statements that
“we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon
information available to us as of the date of this prospectus, and although we believe such information forms a reasonable basis for such
statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a
thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors
are cautioned not to unduly rely upon these statements.

This prospectus also contains
estimates, projections and other information concerning our industry, our business, and our target markets for certain diseases, including
data regarding the estimated size of those markets. Information that is based on estimates, forecasts, projections, market research or
similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and
circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other
data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical
and general publications, government data, and similar sources.

| 20 |

<div align='center'>USE OF PROCEEDS</div>

Assuming we sell all Units offered pursuant to this prospectus,
we estimate the net proceeds from this offering will be approximately $15.5 million, based on an assumed combined public offering price
of $5.33 per Unit with Depositary Shares (the last reported sale price of our Depositary Shares on the NASDAQ Capital Market on November
12, 2025) and $5.3299 per Unit with Pre-Funded Warrants (the last reported sale price of our Depositary Shares on the NASDAQ Capital Market
on November 12, 2025, minus $0.0001), after deducting placement agent fees and estimated offering expenses payable by us as described
in “Plan of Distribution,” and excluding the proceeds, if any, from the cash exercise of the Pre-Funded Warrants and
Series L Warrants sold in this offering.

We intend to use the net proceeds
from this offering to fund our development programs, for working capital and other general corporate purposes.

The allocation of the net
proceeds of the offering represents our estimates based